文献速递前列腺癌

淋巴结阳性前列腺癌辅助放疗:何时与何人仍存争议

Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?
PubMed 文献 · BJU Int · 2020-09-25

该回顾性队列纳入187例根治性前列腺切除及扩大盆腔淋巴结清扫后病理淋巴结阳性(pN1)前列腺癌患者,均在术后6个月内接受辅助放疗。5年局部、远处、生化无复发生存率及总生存率分别为68%、71%、56%和94%,阳性淋巴结数目是生化、局部和远处无复发生存的独立预测因子,最佳阈值为5枚。

要点

  • pN1前列腺癌术后辅助放疗5年总生存率达94%,远处无复发生存率71%。
  • 阳性淋巴结数目是生化、局部和远处无复发生存的独立预测因子,最佳阈值为5枚。
  • 初始PSA升高和脉管侵犯增加生化复发风险,ISUP分级组<3与更好的局部和远处无复发生存相关。

核心结论

  • pN1前列腺癌患者接受辅助治疗后结局令人鼓舞,阳性淋巴结数目在预测生化、临床和远处无复发生存中起关键作用。
  • 仍需大型前瞻性队列研究和随机临床试验来确认结果并识别最受益于辅助放疗的pN1亚组。

研究设计与样本

  • 回顾性队列研究,纳入187例 consecutive pN1前列腺癌患者,在意大利米兰IEO接受辅助放疗。
  • 辅助放疗于根治性前列腺切除术后6个月内对瘤床和盆腔实施,雄激素剥夺治疗按指南进行。
  • 采用单因素和多因素Cox回归分析预测生化、局部、远处无复发生存和总生存,并计算Youden指数确定阳性淋巴结数目的最佳阈值。

主要发现

  • 5年局部无复发生存率为68%,远处无复发生存率为71%,生化无复发生存率为56%,总生存率为94%。
  • 中位随访时间为49个月。
  • 阳性淋巴结数目与生化、局部和远处无复发生存显著相关,区分生化和临床复发的最佳阈值为5枚阳性淋巴结。
  • 多因素分析证实阳性淋巴结数目是生化、局部和远处无复发生存的独立预测因子,但不是总生存的独立预测因子。
  • 多因素分析显示初始PSA升高和肿瘤脉管侵犯增加生化复发风险;ISUP分级组<3(组1或2 compared to 组3)与局部和远处无复发生存风险显著降低相关。

关键数值与推荐

  • 5年局部无复发生存率68%,远处无复发生存率71%,生化无复发生存率56%,总生存率94%。
  • 区分生化和临床复发的最佳阳性淋巴结数目阈值为5枚。
  • 中位随访49个月。

临床怎么用

  • 对于pN1前列腺癌患者,根治性前列腺切除及扩大盆腔淋巴结清扫后6个月内可考虑辅助放疗,并联合按指南的雄激素剥夺治疗。
  • 阳性淋巴结数目(尤其≥5枚)可用于风险分层,辅助识别更可能从辅助放疗中获益的患者。
  • 初始PSA升高和脉管侵犯提示生化复发风险增加,需加强随访。

局限性

  • 回顾性队列设计,样本量有限(187例),可能存在选择偏倚。
  • 需要大型前瞻性队列研究和随机临床试验确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of adjuvant radiotherapy (aRT) in patients with prostate cancer (PCa) found to have pathological positive lymph nodes (pN1s) after radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) with regard to distant recurrence-free survival (RFS), according to both main tumour pathological characteristics and number of positive lymph nodes. Biochemical RFS, local RFS, overall survival (OS) and acute and late toxicity were assessed as secondary endpoints. PATIENTS AND METHODS: A retrospective cohort of 187 consecutive patients with pN1 PCa were treated with aRT at the IEO, European Institute of Oncology IRCCS, Milan, Italy. aRT on the tumour bed and pelvis was administered within 6 months of RP. Androgen deprivation therapy was administered according to the guidelines. Univariate and multivariate Cox regression analyses predicting biochemical RFS, local RFS, distant RFS and OS rates were performed to assess whether the number of pN1s represented an independent prognostic factor. The Youden index was computed to find the optimal threshold for the number of pN1s able to discriminate between patients with or without biochemical and clinical relapse. RESULTS: At 5 years, local RFS, distant RFS, biochemical RFS and OS were 68%, 71%, 56% and 94%, respectively. The median follow-up was 49 months. The number of pN1s was significantly associated with biochemical RFS, local RFS and distant RFS. The best threshold for discriminating between patients with or without biochemical and clinical relapse was five pN1s. In multivariate analyses, the number of pN1s was confirmed to be an independent predictor of biochemical RFS, local RFS and distant RFS, but not of OS. Multivariate analyses also showed an increased risk of biochemical relapse for increasing values of initial prostate-specific antigen and for patients with tumour vascular invasion. Local and distant RFS were also inversely correlated with significantly reduced risk for International Society of Urological Pathology grade group <3 (group 1 or 2 compared to group 3). CONCLUSIONS: Our data confirmed the encouraging outcomes of patients with pN1 PCa treated with adjuvant treatments and the key role represented by the number of pN1s in predicting biochemical RFS, clinical RFS and distant RFS. Large prospective cohort studies and randomized clinical trials are needed to confirm these results and to identify the subgroup of patients with pN1 PCa who would most benefit from aRT.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Marvaso G, Montesano M, Corrao G, et al. Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom? BJU Int. 2020. PMID: 32969548. doi:10.1111/bju.15228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。